BAYER AKTIENGESELLSCHAFT

Their core work

Bayer is a global life sciences and pharmaceutical company headquartered in Leverkusen, Germany, with deep capabilities in drug development, clinical trials, and translational safety. Within H2020, Bayer contributes pharmaceutical industry expertise to large-scale health data initiatives, pain research, oncology, cardiovascular disease, and diabetes biomarker discovery. They bring real-world clinical data, drug safety knowledge, and industrial-scale screening capabilities to public-private research consortia, particularly through IMI (Innovative Medicines Initiative) partnerships.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), Bayer's involvement centered on traditional pharmaceutical strengths: toxicology, personalized medicine, biomarker discovery, and even a foray into marine enzyme mining (INMARE). From 2019 onward, the focus shifted decisively toward AI-driven health data analysis, FAIR data standards, and large-scale clinical data networks — reflecting the pharma industry's digital transformation. The growing emphasis on neurodegeneration, oncology, and deep learning signals Bayer's push to integrate computational methods into its drug development pipeline.

Bayer is rapidly building capacity in AI/ML for drug development and health data interoperability — future partners should expect data-intensive, computationally driven collaborations.

How they like to work

Bayer overwhelmingly participates as a consortium member rather than leading projects — coordinating just 1 of 59 projects (CONSENS, a process industry project). They operate in large, multi-partner consortia (765 unique partners across 37 countries), particularly within IMI public-private partnerships where pharma companies typically contribute data, clinical expertise, and co-funding rather than project management. This makes them a reliable, well-resourced industrial partner who brings real-world pharmaceutical assets to the table without competing for leadership roles.

Bayer has one of the broadest collaboration networks in H2020 pharma, with 765 unique partners across 37 countries. Their reach spans all major EU research nations and reflects their heavy involvement in IMI mega-consortia that typically include 20-50 partners each.

What sets them apart

Bayer brings something few academic or SME partners can: real-world pharmaceutical industry data, clinical trial infrastructure, and regulatory experience at global scale. Their participation signals project credibility to regulators and investors alike. For consortium builders, Bayer is the kind of industrial anchor that strengthens any IMI or health-focused proposal — they know the regulatory landscape, have proprietary compound libraries and patient datasets, and their involvement often unlocks IMI co-funding from EFPIA.

Highlights from their portfolio

• CONSENS
  Bayer's only coordinated project (EUR 914K EC funding) — an outlier focused on process intensification rather than pharma, revealing broader industrial capabilities.
• EHDEN
  Massive European health data network using OMOP/FAIR standards — positions Bayer at the center of Europe's push for interoperable health data infrastructure.
• IMI-PainCare
  Addresses a critical unmet medical need (chronic pain, endometriosis) with deep phenotyping and biomarker approaches — high translational and commercial relevance.